Bu sayfada
SYRE Spyre Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 4, 2026
$93,19
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$15,8652 haftanın en düşüğü
$110,1852 haftanın en yükseği
Piyasa Değeri (MRQ)
$8.21B
P/E
29.1
Hisse Başına Kâr
$13.76
Gelir
$0
rozetleriniz
52 Haftlık Aralık
$16–$110
Analist Derecelendirmesi
STRONG BUY
Fiyat Hedefi
$120
P/E
29.1
ROE
-26.5%
Net Kâr Marjı
·
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
SYRE Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$93.19
Piyasa Değeri (MRQ)
$8.21B
P/E
29.1
Hisse Başına Kâr
$13.76
Gelir
$0
ROE
-26.5%
52 Haftlık Aralık
$16–$110
SYRE Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 08 Eylül 2023 | 1-for-25 | Ters |
Spyre Therapeutics, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
sektörHealthcare
endüstriBiotechnology
çalışanlar125
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$02016-12-31 → 2025-12-31
Hisse Başına Kâr$13.762020-12-31 → 2023-12-31
Serbest Nakit Akışı·2016-12-31 → 2024-12-31
Net kar marjı·2018-12-31 → 2023-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | SYRE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | 29.15Y ort. ≈2.7 | ≈2.7 | · | · | |
| F/D (MRQ) | 7.55Y ort. ≈22.7 | ≈22.7 | 7.1 | Adil değer | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -43.45Y ort. ≈-35.6 | ≈-35.6 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 10.35Y ort. ≈19.0 | ≈19.0 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | SYRE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| ROA | -22.4%5Y ort. ≈-51.8% | ≈-51.8% | -42.7% | En üst düzey | |
| ROE | -26.5%5Y ort. ≈-72.2% | ≈-72.2% | -56.0% | En üst düzey | |
| ROIC | -29.3%5Y ort. ≈-79.1% | ≈-79.1% | -37.2% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | SYRE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 18.55Y ort. ≈8.4 | ≈8.4 | 7.3 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 1.55Y ort. ≈1.6 | ≈1.6 | 5.5 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | SYRE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -62.0% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | SYRE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.0 | ≈0.0 | 0.0 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$0.00 | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
27.7%
Sonraki Rapor
Kas 02, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 3, 2026 | $-0.36 | $-0.77 | 53.5% |
| 31 Mart 2026 | May 7, 2026 | $-0.74 | $-0.68 | -8.9% |
| 31 Aralık 2025 | $-0.70 | $-0.79 | 11.4% | |
| 30 Eylül 2025 | $-0.15 | $-0.76 | 80.3% | |
| 30 Haziran 2025 | $-0.77 | $-0.77 | -0.17% | |
| 31 Mart 2025 | $-0.60 | $-0.86 | 30.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.0K | $2M | $19M | $0 | $0 | $4M | $5M | $5M | |
| R&D Expense | · | · | · | $59M | $57M | $60M | $65M | $37M | $23M | $18M | |
| SG&A Expense | $48M | $46M | $40M | $29M | $27M | $22M | $16M | $13M | $10M | $8M | |
| Operating Expenses | $210M | $209M | $243M | $87M | $84M | $81M | $80M | $49M | $33M | $27M | |
| Operating Income | $-210M | $-209M | $-242M | $-85M | $-66M | $-81M | $-80M | $-45M | $-28M | $-22M | |
| Other Non-op | $29M | $-21M | $-19M | $-7.0K | $-122.0K | $-5.0K | $-63.0K | $-57.0K | $-42.0K | $-36.0K | |
| Pretax Income | $-155M | $-208M | $-339M | $-84M | $-66M | $-81M | $-78M | · | · | · | |
| Income Tax | $-15.0K | $51.0K | $-26.0K | $-136.0K | $141.0K | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-155M | $-208M | $-339M | $-84M | $-66M | $-81M | $-78M | $-44M | $-27M | $-22M | |
| EPS (Basic) | · | · | $13.76 | $-24.86 | $-25.02 | $-1.52 | · | · | · | · | |
| EPS (Diluted) | · | · | $13.76 | $-24.86 | $-25.02 | $-1.52 | · | · | · | · | |
| Shares (Basic) | · | · | 6,897,065 | 3,371,231 | 2,629,784 | 53,371,730 | · | · | · | · | |
| Shares (Diluted) | · | · | 6,897,065 | 3,371,231 | 2,629,784 | 53,371,730 | · | · | · | · | |
| EBITDA | $-210M | $-209M | $-242M | $-83M | $-64M | $-80M | $-80M | $-45M | $-27M | $-22M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $86M | $89M | $189M | $35M | $15M | $90M | $19M | $22M | $13M | $48M | |
| Short-term Investments | · | · | · | · | · | · | · | $52M | $37M | $16M | |
| Prepaid Expense | $21M | $5M | $2M | $6M | $5M | $4M | $3M | $2M | $2M | $2M | |
| Current Assets | $778M | $608M | $342M | $62M | $99M | $150M | $75M | $77M | $55M | $66M | |
| PP&E (Net) | · | · | $0 | $3M | $5M | $6M | $2M | $1M | $854.0K | $599.0K | |
| PP&E (Gross) | · | · | $0 | $7M | $7M | $8M | $3M | $2M | $1M | $839.0K | |
| Accum. Depreciation | · | · | $0 | $4M | $3M | $2M | $1M | $752.0K | $487.0K | $240.0K | |
| Other Non-current Assets | $0 | $10.0K | $9.0K | $683.0K | $842.0K | $115.0K | $67.0K | $50.0K | $232.0K | $40.0K | |
| Total Assets | $778M | $608M | $342M | $71M | $110M | $162M | $83M | $78M | $56M | $67M | |
| Accounts Payable | · | · | · | $677.0K | $3M | $2M | $3M | $663.0K | $389.0K | $168.0K | |
| Current Liabilities | $59M | $54M | $32M | $15M | $20M | $16M | $18M | $10M | $6M | $4M | |
| Capital Leases | · | · | $0 | $4M | $5M | $5M | $5M | · | · | · | |
| Other Non-current Liabilities | $0 | · | · | $0 | $16.0K | $214.0K | $31.0K | $72.0K | $111.0K | $132.0K | |
| Total Liabilities | $63M | $91M | $73M | $21M | $26M | $22M | $23M | $10M | $6M | $4M | |
| Common Stock | $15.0K | $13.0K | $10.0K | $6.0K | $5.0K | $5.0K | $3.0K | $2.0K | $2.0K | $1.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | $184M | $123M | $108M | |
| Retained Earnings | $-1.13B | $-972M | $-764M | $-426M | $-342M | $-276M | $-195M | $-117M | $-73M | $-45M | |
| AOCI | $869.0K | $180.0K | $302.0K | $-48.0K | $-20.0K | $11.0K | $51.0K | $-27.0K | $-102.0K | $-4.0K | |
| Stockholders' Equity | $715M | $518M | $184M | $50M | $84M | $140M | $60M | $67M | $50M | $63M | |
| Liabilities + Equity | $778M | $608M | $342M | $71M | $110M | $162M | $83M | $78M | $56M | $67M | |
| Shares Outstanding | 78,189,811 | 60,257,000 | 36,057,000 | 2,614,000 | 1,974,000 | 1,918,000 | 29,084,437 | 24,140,097 | 16,670,188 | 13,430,833 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $0 | $0 | $744.0K | $2M | $2M | $996.0K | $418.0K | $293.0K | $249.0K | $132.0K | |
| Stock-based Comp | $38M | $45M | $26M | $7M | $8M | $6M | $5M | $4M | $2M | $1M | |
| Other Non-cash | $-52M | $6M | $212M | $-5M | $2M | $-2M | $7M | $8M | $-120.0K | $2M | |
| Operating Cash Flow | $-169M | $-157M | $-100M | $-80M | $-54M | $-76M | $-66M | $-32M | $-25M | $-19M | |
| CapEx | · | $0 | $0 | $38.0K | $573.0K | $4M | $1M | $422.0K | $619.0K | $212.0K | |
| Investing Cash Flow | $-143M | $-353M | $-108M | $57M | $-23M | $-8M | $-2M | $-15M | $-23M | $-12M | |
| Stock Issued | · | · | $85M | $0 | $0 | · | · | · | · | · | |
| Net Stock Activity | · | · | $85M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $309M | $411M | $361M | $43M | $1M | $155M | $66M | $57M | $12M | $49M | |
| Net Change in Cash | $-4M | $-100M | $153M | $19M | $-75M | $71M | $-2M | $10M | $-35M | $18M | |
| Taxes Paid | $-15.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-157M | $-100M | $-80M | $-54M | $-80M | $-67M | $-33M | $-25M | $-19M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -27348.0% | -3640.2% | -350.3% | · | · | -1169.3% | · | · | |
| Net Margin | · | · | -38238.2% | -3598.7% | -351.1% | · | · | -1140.6% | · | · | |
| Pretax Margin | · | · | -38241.1% | -3604.6% | -350.4% | · | · | · | · | · | |
| EBITDA Margin | · | · | -27264.0% | -3573.0% | -341.9% | · | · | -1161.8% | · | · | |
| ROA | -22.4% | -43.8% | · | -92.6% | -48.5% | -66.1% | -97.3% | -66.3% | -44.2% | -41.0% | |
| ROE | -26.5% | -49.2% | · | -142.2% | -70.8% | -58.6% | -111.9% | -67.7% | -48.1% | -106.5% | |
| ROIC | -29.3% | -40.3% | · | -168.3% | -78.4% | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 11.3 | · | 4.2 | 4.9 | 9.1 | 4.1 | 7.5 | 9.8 | 16.8 | |
| Quick Ratio | 1.5 | 1.7 | · | 2.4 | 0.8 | 5.5 | 1.0 | 7.3 | 8.9 | 16.0 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $9.15 | $8.59 | · | $0.77 | $1.70 | $2.92 | $2.07 | $2.79 | $3.02 | $4.69 | |
| Revenue / Share | · | · | $0.13 | $0.03 | · | · | · | · | · | · | |
| Cash Flow / Share | · | · | $-14.49 | $-0.95 | · | · | · | · | · | · | |
| Cash / Share | $1.10 | $1.48 | · | $0.53 | $0.31 | $1.88 | $0.66 | $0.93 | $0.77 | $3.56 | |
| EPS (TTM) | $3.23 | $3.23 | $13.76 | $-24.86 | $-25.02 | $-1.52 | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -62.0% | -87.6% | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $886.0K | $2M | $19M | $0 | $0 | $4M | $5M | $5M | |
| Net Income TTM | $-155M | $-208M | $-339M | $-84M | $-66M | $-81M | $-78M | $-44M | $-27M | $-22M | |
| Market Cap | $2.56B | $1.40B | · | $735M | $5.86B | $9.44B | $5.56B | $4.52B | $2.25B | $1.46B | |
| P/E | 10.1 | 7.2 | 1.6 | -0.5 | -4.7 | -129.4 | · | · | · | · | |
| P/S | · | · | · | 315.7 | 312.8 | · | · | 1162.6 | 433.2 | 315.6 | |
| P/B | 3.6 | 2.7 | · | 14.6 | 69.8 | 67.5 | 92.5 | 67.0 | 44.8 | 23.2 | |
| P / Tangible Book | 3.6 | 2.7 | 4.2 | 14.6 | 69.8 | 67.5 | · | · | · | · | |
| P / Cash Flow | -15.1 | -8.9 | · | -9.2 | -109.1 | -124.5 | -84.6 | -140.4 | -91.6 | -77.5 | |
| P / FCF | · | -8.9 | · | -9.2 | -108.0 | -117.9 | -82.7 | -138.6 | -89.3 | -76.7 | |
| Earnings Yield | 9.9% | 13.9% | 63.9% | -221.0% | -21.1% | -0.77% | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $688.0K | $198.0K | $174.0K | $625.0K | $1M | |
| R&D Expense | · | · | · | · | · | · | · | · | · | · | · | · | $14M | $12M | $15M | $17M | |
| SG&A Expense | $16M | $15M | $13M | $12M | $12M | $12M | $11M | $11M | $12M | $13M | $9M | $12M | $5M | $7M | $8M | $9M | |
| Operating Expenses | $42M | $46M | $57M | $57M | $42M | $54M | $61M | $55M | $44M | $48M | $18M | $160M | $19M | $19M | $23M | $26M | |
| Operating Income | $-42M | $-46M | $-57M | $-57M | $-42M | $-54M | $-61M | $-55M | $-44M | $-48M | $-18M | $-159M | $-19M | $-19M | $-22M | $-24M | |
| Other Non-op | $-5M | $-30M | $-12M | $40M | $-656.0K | $2M | $-818.0K | $-19M | $-610.0K | $-483.0K | $2M | $-8.0K | $-72.0K | $24.0K | $5.0K | $-30.0K | |
| Pretax Income | $-36M | $-69M | $-63M | $-11M | $-37M | $-45M | $-56M | $-69M | $-39M | $-44M | $-40M | $-217M | $-18M | $-18M | $-22M | $-24M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $-15.0K | $1.0K | $18.0K | $0 | $32.0K | $3.0K | $7.0K | $-36.0K | $-209.0K | $9.0K | $0 | |
| Net Income | $-36M | $-69M | $-63M | $-11M | $-37M | $-45M | $-56M | $-69M | $-39M | $-44M | $-40M | $-217M | $-18M | $-18M | $-22M | $-24M | |
| EPS (Basic) | · | · | · | · | · | · | · | $1.06 | $0.59 | $0.72 | $0.86 | $40.14 | $-4.89 | $-4.84 | $-0.27 | $-0.37 | |
| EPS (Diluted) | $-0.35 | $-0.74 | · | $-0.15 | · | · | · | $1.06 | $0.59 | $0.72 | $0.86 | $40.14 | $-4.89 | $-4.84 | $-0.27 | $-0.37 | |
| Shares (Basic) | · | · | · | · | · | · | · | 50,889,433 | 45,316,264 | 36,512,662 | 4,293,812 | 3,822,605 | 3,770,506 | 3,767,918 | 82,209,032 | 65,996,161 | |
| Shares (Diluted) | · | · | · | · | · | · | · | 50,889,433 | 45,316,264 | 36,512,662 | 4,293,812 | 3,822,605 | 3,770,506 | 3,767,918 | 82,209,032 | 65,996,161 | |
| EBITDA | $-42M | $-46M | · | $-57M | $-42M | $-54M | · | $-55M | $-44M | $-48M | $-18M | $-159M | $-18M | $-19M | $-22M | $-24M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $162M | $97M | $86M | $65M | $82M | $48M | $89M | $72M | $45M | $228M | $91M | $235M | $35M | $39M | $37M | $15M | |
| Prepaid Expense | $28M | $22M | $21M | $18M | $12M | $5M | $5M | $7M | $10M | $3M | $2M | $3M | $6M | $8M | $8M | $5M | |
| Current Assets | $1.17B | $764M | $778M | $505M | $539M | $570M | $608M | $421M | $436M | $487M | $206M | $240M | $44M | $82M | $97M | $73M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $3M | $4M | $4M | $4M | |
| Other Non-current Assets | · | · | $0 | $0 | $0 | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | $10.0K | $78.0K | $749.0K | $752.0K | $800.0K | |
| Total Assets | $1.17B | $764M | $778M | $505M | $539M | $570M | $608M | $421M | $436M | $488M | $207M | $244M | $52M | $92M | $107M | $83M | |
| Accounts Payable | · | · | · | · | · | · | · | · | · | · | · | $3M | $2M | $4M | $2M | $3M | |
| Current Liabilities | $63M | $85M | $59M | $46M | $83M | $71M | $54M | $58M | $22M | $43M | $45M | $232M | $13M | $18M | $16M | $16M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $4M | $4M | $4M | $4M | |
| Other Non-current Liabilities | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $8.0K | |
| Total Liabilities | $72M | $93M | $63M | $50M | $83M | $87M | $91M | $94M | $62M | $82M | $66M | $254M | $19M | $24M | $23M | $22M | |
| Common Stock | $16.0K | $15.0K | $15.0K | $13.0K | $13.0K | $13.0K | $13.0K | $12.0K | $12.0K | $10.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | |
| Retained Earnings | $-1.23B | $-1.20B | $-1.13B | $-1.07B | $-1.05B | $-1.02B | $-972M | $-916M | $-847M | $-808M | $-701M | $-661M | $-444M | $-407M | $-389M | $-366M | |
| AOCI | $-2M | $-767.0K | $869.0K | $791.0K | $454.0K | $682.0K | $180.0K | $1M | $-553.0K | $-363.0K | $-132.0K | $11.0K | $-6.0K | $-184.0K | $-220.0K | $-153.0K | |
| Stockholders' Equity | $1.10B | $671M | $715M | $455M | $456M | $483M | $518M | $327M | $374M | $152M | $-245M | $-207M | $34M | $68M | $84M | $62M | |
| Liabilities + Equity | $1.17B | $764M | $778M | $505M | $539M | $570M | $608M | $421M | $436M | $488M | $207M | $244M | $52M | $92M | $107M | $83M | |
| Shares Outstanding | 88,064,133 | 78,839,858 | 78,189,811 | 60,471,793 | 60,372,927 | 60,275,561 | 60,257,023 | 51,395,608 | 50,783,384 | 36,629,680 | 4,048,687 | 81,001,676 | 65,395,159 | 61,511,078 | 61,172,510 | 49,419,873 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $360.0K | $384.0K | $401.0K | $378.0K | $403.0K | |
| Stock-based Comp | $14M | $13M | $10M | $10M | $9M | $9M | $9M | $13M | $9M | $14M | $5M | $2M | $2M | $2M | $2M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | $-4M | |
| Operating Cash Flow | $-70M | $-57M | $-45M | $-37M | $-47M | $-41M | $-37M | $-29M | $-62M | $-29M | $-35M | $-17M | $-18M | $-15M | $-21M | $-26M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | $1.0K | $0 | $37.0K | |
| Investing Cash Flow | $-298M | $57M | $-247M | $25M | $79M | $-61.0K | $-171M | $43M | $-121M | $-105M | $-98M | $7M | $18M | $16M | $750.0K | $26M | |
| Financing Cash Flow | $433M | $12M | $313M | $-5M | $731.0K | $125.0K | $226M | $13M | $360.0K | $172M | $-13M | $210M | $10.0K | $-130.0K | $43M | $12.0K | |
| Net Change in Cash | $65M | $11M | $21M | $-17M | $33M | $-41M | $18M | $26M | $-182M | $39M | $-145M | $200M | $137.0K | $1M | $23M | $-515.0K | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-26M |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | -23146.2% | -9498.0% | -10778.7% | -3587.7% | -1794.5% | |
| Net Margin | · | · | · | · | · | · | · | · | · | · | · | -31552.5% | -9304.0% | -10479.3% | -3571.7% | -1794.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -31551.5% | -9322.2% | -10599.4% | -3570.2% | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | · | · | -23146.2% | -9304.0% | -10778.7% | -3587.7% | -1764.9% | |
| ROA | -4.2% | -10.3% | · | -2.4% | -7.5% | -8.5% | · | -22.0% | · | · | -26.8% | -124.0% | -27.2% | -16.5% | -17.6% | -19.8% | |
| ROE | -4.7% | -12.0% | · | -2.9% | -8.8% | -14.1% | · | -168.4% | · | · | 45.1% | 352.4% | -38.7% | -21.5% | -22.0% | -26.4% | |
| ROIC | -3.8% | -6.8% | · | -12.5% | -9.2% | -11.1% | · | -16.9% | -11.8% | -31.4% | 7.5% | 76.8% | -55.8% | -27.5% | -26.7% | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.5 | 9.0 | · | 10.9 | 6.5 | 8.1 | · | 7.3 | 19.7 | 11.4 | 4.6 | 1.0 | 3.5 | 4.7 | 6.1 | 4.5 | |
| Quick Ratio | 2.6 | 1.1 | · | 1.4 | 1.0 | 0.7 | · | 1.2 | 2.0 | 5.3 | 2.0 | 1.0 | 2.8 | 2.2 | 2.4 | 0.9 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $12.50 | $8.51 | · | $7.53 | $7.55 | $8.01 | · | $6.37 | $7.37 | $4.16 | $-60.61 | $-2.56 | $0.51 | $1.10 | $1.38 | $1.25 | |
| Revenue / Share | · | · | · | · | · | · | · | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.01 | · | |
| Cash Flow / Share | · | · | · | · | · | · | · | · | · | $-0.78 | · | · | $-0.19 | · | · | · | |
| Cash / Share | $1.84 | $1.23 | · | $1.07 | $1.35 | $0.80 | · | $1.39 | $0.89 | $6.21 | $22.38 | $2.91 | $0.54 | $0.63 | $0.61 | $0.30 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $688.0K | $1M | $1M | $1M | $6M | $7M | $20M | |
| Net Income TTM | $-179M | $-179M | · | $-149M | $-207M | $-209M | · | $-215M | $-186M | $-364M | $-294M | $-273M | $-78M | $-85M | $-88M | $-72M | |
| Market Cap | $7.82B | $3.98B | · | $1.01B | $904M | $973M | · | $1.51B | $1.19B | $1.39B | $50M | $913M | $474M | $809M | $772M | $2.84B | |
| P/S | · | · | · | · | · | · | · | · | · | 2019.4 | 47.1 | 743.7 | 407.0 | 139.3 | 109.9 | 141.4 | |
| P/B | 7.1 | 5.9 | · | 2.2 | 2.0 | 2.0 | · | 4.6 | 3.2 | 9.1 | -0.2 | -4.4 | 14.1 | 12.0 | 9.2 | 46.1 | |
| P / Tangible Book | 7.1 | 5.9 | · | 2.2 | 2.0 | 2.0 | · | 4.6 | 3.2 | 9.1 | · | · | 14.1 | 12.0 | 9.2 | 46.1 | |
| P / Cash Flow | · | -69.3 | · | · | · | -23.7 | · | · | · | -48.7 | · | · | -26.9 | · | · | -108.2 |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $0 | $0 | $886.0K | $2M | $19M |
| Faaliyet Kâr Marjı % | · | · | -27348.0% | -3640.2% | -350.3% |
| Net Gelir | $-155M | $-208M | $-339M | $-84M | $-66M |
| Seyreltilmiş Hisse Başı Kâr | · | · | $13.76 | $-24.86 | $-25.02 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 13.3 | 11.3 | · | 4.2 | 4.9 |
| Cari Oran | 1.5 | 1.7 | · | 2.4 | 0.8 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | · | $-157M | $-100M | $-80M | $-54M |
Kurumsal Sahipler (13F) 277 dosya · $8.3B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
277
Tutulan Değer
$8.3B
Yeni pozisyonlar
94
Çıkan pozisyonlar
21
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 94 (+34 önceki Ç'ye göre) | 21 (+10 önceki Ç'ye göre) | 105 (+38 önceki Ç'ye göre) | 56 (+8 önceki Ç'ye göre) | +11.3M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| FMR LLC | $1.156.464.882 | 13.026.187 | 13,95% | Hisse senetleri |
| BlackRock, Inc. | $577.656.391 | 6.506.605 | 6,97% | Hisse senetleri |
| PERCEPTIVE ADVISORS LLC | $383.484.855 | 4.319.496 | 4,63% | Hisse senetleri |
| RTW INVESTMENTS, LP | $377.492.205 | 4.251.996 | 4,55% | Hisse senetleri |
| Paradigm Biocapital Advisors LP | $340.984.271 | 3.840.778 | 4,11% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $306.173.899 | 3.448.681 | 3,69% | Hisse senetleri |
| STATE STREET CORP | $271.437.392 | 3.057.416 | 3,27% | Hisse senetleri |
| Venrock Adviser, LLC | $265.048.073 | 2.985.448 | 3,20% | Hisse senetleri |
| Driehaus Capital Management LLC | $248.509.957 | 2.799.166 | 3,00% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $239.258.122 | 2.562.265 | 2,89% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $206.866.100 | 2.330.098 | 2,50% | Hisse senetleri |
| Capital World Investors | $205.574.795 | 2.315.553 | 2,48% | Hisse senetleri |
| TCG Crossover Management, LLC | $168.733.670 | 1.900.582 | 2,04% | Hisse senetleri |
| TANG CAPITAL MANAGEMENT LLC | $167.989.516 | 1.892.200 | 2,03% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $157.837.878 | 1.777.854 | 1,90% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $152.905.794 | 1.722.300 | 1,84% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $140.406.014 | 1.581.505 | 1,69% | Hisse senetleri |
| VANGUARD GROUP INC | $132.189.024 | 4.035.074 | 1,59% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $131.222.079 | 1.478.059 | 1,58% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $130.767.861 | 1.472.943 | 1,58% | Hisse senetleri |
| Remedium Capital Partners, LLC | $129.988.924 | 1.464.169 | 1,57% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $113.561.517 | 1.279.134 | 1,37% | Hisse senetleri |
| JPMORGAN CHASE & CO | $98.870.628 | 1.093.026 | 1,19% | Hisse senetleri |
| Holocene Advisors, LP | $90.126.793 | 1.015.170 | 1,09% | Hisse senetleri |
| MARSHALL WACE, LLP | $88.042.506 | 991.693 | 1,06% | Hisse senetleri |
| Polar Capital Holdings Plc | $87.715.439 | 988.009 | 1,06% | Hisse senetleri |
| Siren, L.L.C. | $85.992.130 | 968.598 | 1,04% | Hisse senetleri |
| Capital International Investors | $84.802.301 | 955.196 | 1,02% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $83.586.597 | 1.656.164 | 1,01% | Hisse senetleri |
| BRAIDWELL LP | $78.079.080 | 879.467 | 0,94% | Hisse senetleri |
| Commodore Capital LP | $75.177.661 | 846.786 | 0,91% | Hisse senetleri |
| UBS Group AG | $74.847.843 | 843.071 | 0,90% | Hisse senetleri |
| NORTHERN TRUST CORP | $59.884.685 | 674.529 | 0,72% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57.969.611 | 652.958 | 0,70% | Hisse senetleri |
| Pictet Asset Management Holding SA | $55.766.092 | 628.138 | 0,67% | Hisse senetleri |
| EMERALD ADVISERS, LLC | $50.376.435 | 567.430 | 0,61% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $49.182.345 | 553.980 | 0,59% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $48.952.315 | 551.389 | 0,59% | Hisse senetleri |
| Candriam S.C.A. | $48.454.915 | 546.312 | 0,58% | Hisse senetleri |
| MORGAN STANLEY | $44.386.718 | 499.963 | 0,54% | Hisse senetleri |
| VOYA INVESTMENT MANAGEMENT LLC | $38.325.793 | 431.694 | 0,46% | Hisse senetleri |
| EMERALD MUTUAL FUND ADVISERS TRUST | $35.624.839 | 401.271 | 0,43% | Hisse senetleri |
| SAMLYN CAPITAL, LLC | $35.518.659 | 400.075 | 0,43% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $31.612.960 | 356.082 | 0,38% | Hisse senetleri |
| Integral Health Asset Management, LLC | $28.853.500 | 325.000 | 0,35% | Hisse senetleri |
| Woodline Partners LP | $27.171.030 | 306.049 | 0,33% | Hisse senetleri |
| JENNISON ASSOCIATES LLC | $26.916.321 | 303.180 | 0,32% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $25.211.922 | 283.982 | 0,30% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $23.075.964 | 259.923 | 0,28% | Hisse senetleri |
| Bank of New York Mellon Corp | $21.768.235 | 245.193 | 0,26% | Hisse senetleri |
Aktivistler ve %5+ sahipler 2 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin, Tomas Kiselak ×8 başvurular | 23 Haziran 2026 | 9,99% | Değişiklik | Yönetim kurulu kampanyası | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker, Julian C. Baker ×3 başvurular | 10 Şubat 2022 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 37 içeriden öğrenenler · 21 yöneticiler · 19 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Cameron Turtle | Chief Executive Officer | 01 Ekim 2026 S | 537.540 | 0 | 40 | $-11.374.650 |
| Jeff Marc Goldberg | President and CEO | 29 Kasım 2022 A | · | 0 | 0 | $0 |
| Anthony G. Quinn | President & CEO | 16 Mart 2022 P | 550.540 | 0 | 0 | $0 |
| David George Lowe | CEO and President | 20 Mart 2017 A | 5.658 | 0 | 0 | $0 |
| Scott L Burrows | Chief Financial Officer | 01 Ekim 2026 M | 79.762 | 0 | 26 | $-9.124.219 |
| Jonathan Alspaugh | President and CFO | 22 Haziran 2023 A | 165.372 | 0 | 0 | $0 |
| Charles N York II | Chief Financial Officer and VP | 14 Şubat 2020 A | 34.787 | 0 | 0 | $0 |
| Leslie Sloan | Chief Operating Officer | 23 Ağustos 2022 A | · | 0 | 0 | $0 |
| Heidy King-Jones | Chief Legal Officer and Corporate Secretary | 01 Ekim 2026 M | 2.845 | 0 | 10 | $-5.114.431 |
| Sheldon Sloan | Chief Medical Officer | 01 Temmuz 2026 M | 0 | 0 | 11 | $-7.354.471 |
| Linda L Neuman | Chief Medical Officer | 23 Şubat 2023 A | · | 0 | 0 | $0 |
| James Paul Kastenmayer | General Counsel | 23 Şubat 2023 A | · | 0 | 0 | $0 |
| Jr. Michael Conick Hanley | Chief Business Officer | 23 Şubat 2023 A | 36.200 | 0 | 0 | $0 |
| Steven Weber | VP, Controller&Princ Acctg Off | 17 Şubat 2022 A | · | 0 | 0 | $0 |
| Madduri Ravin Rao | Chief Medical Officer | 14 Şubat 2020 A | · | 0 | 0 | $0 |
| James Wooldridge | Chief Medical Officer | 28 Şubat 2019 A | · | 0 | 0 | $0 |
| Aaron Schuchart | Chief Business Officer | 28 Şubat 2019 A | 2.500 | 0 | 0 | $0 |
| Scott W Rowlinson | VP, Research | 22 Ağustos 2017 A | 11.204 | 0 | 0 | $0 |
| Joseph E Tyler | VP, Manufacturing | 22 Ağustos 2017 A | 42.428 | 0 | 0 | $0 |
| Henry Hebel | VP, Product Development | 20 Mart 2017 A | · | 0 | 0 | $0 |
| Sandra Rojas-Caro | Chief Medical Officer | 17 Mayıs 2016 A | · | 0 | 0 | $0 |
| Jeffrey W. Albers | Yönetim kurulu üyesi | 07 Ağustos 2026 M | 9.360 | 0 | 3 | $-2.404.190 |
| Michael Thomas Henderson | Yönetim kurulu üyesi | 22 Haziran 2026 S | 68.606 | 0 | 5 | $-7.952.050 |
| Sandra Milligan | Yönetim kurulu üyesi | 27 Mayıs 2026 A | · | 0 | 0 | $0 |
| Mark C. Mckenna | Yönetim kurulu üyesi | 27 Mayıs 2026 A | · | 0 | 0 | $0 |
| Laurie Stelzer | Yönetim kurulu üyesi | 27 Mayıs 2026 A | · | 0 | 0 | $0 |
| Hunter C Smith | Yönetim kurulu üyesi | 22 Haziran 2023 A | · | 0 | 0 | $0 |
| Alison Frances Lawton | Yönetim kurulu üyesi | 22 Haziran 2023 A | · | 0 | 0 | $0 |
| Russell J. Cox | Yönetim kurulu üyesi | 22 Haziran 2023 A | 7.000 | 0 | 0 | $0 |
| Ivana Magovcevic-Liebisch | Yönetim kurulu üyesi | 22 Haziran 2023 A | · | 0 | 0 | $0 |
| Marcio Souza | Yönetim kurulu üyesi | 25 Ağustos 2022 P | 90.000 | 0 | 0 | $0 |
| Armen Shanafelt | Yönetim kurulu üyesi | 07 Haziran 2022 A | 150.000 | 0 | 0 | $0 |
| Sandesh Mahatme | Yönetim kurulu üyesi | 07 Haziran 2022 A | · | 0 | 0 | $0 |
| Bryan V Lawlis | Yönetim kurulu üyesi | 07 Haziran 2022 A | · | 0 | 0 | $0 |
| Suzanne Louise Bruhn | Yönetim kurulu üyesi | 08 Haziran 2020 A | · | 0 | 0 | $0 |
| George Georgiou | Yönetim kurulu üyesi | 13 Ağustos 2018 M | 175.861 | 0 | 0 | $0 |
| Eli Lilly and Company | 10% sahip | 12 Nisan 2016 C | 2.568.543 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 36 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| LABU · Direxion Shares ETF Trust | 0,89% | 44.942 NS | 31 Temmuz 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,82% | 3.847 NS | 31 Temmuz 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,77% | 710 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,75% | 33.756 SH | 02 Ekim 2026 | Günlük |
| FDMO · FIDELITY COVINGTON TRUST | 0,70% | 64.674 NS | 31 Temmuz 2026 | N-PORT |
| ESSC · Strategy Shares | 0,55% | 2.023 NS | 31 Temmuz 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,53% | 6.226 SH | 02 Ekim 2026 | Günlük |
| IBB · iShares Trust | 0,51% | 591.167 SH | 11 Eylül 2026 | Günlük |
| IWO · iShares Trust | 0,43% | 700.908 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,39% | 79.707 SH | 19 Ağustos 2026 | Günlük |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 20.972 NS | 31 Temmuz 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,28% | 2.523 NS | 31 Temmuz 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,25% | 614 NS | 31 Temmuz 2026 | N-PORT |
| RSSL · Global X Funds | 0,24% | 35.657 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,22% | 1.903.999 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 428.619 SH | 19 Ağustos 2026 | Günlük |
| VFMO · VANGUARD WELLINGTON FUND | 0,18% | 39.684 SH | 19 Ağustos 2026 | Günlük |
| ESML · iShares Trust | 0,09% | 29.173 SH | 11 Eylül 2026 | Günlük |
| ISCG · iShares Trust | 0,08% | 8.816 SH | 11 Eylül 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 886.783 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,08% | 26.643 NS | 31 Temmuz 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,07% | 568.910 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,07% | 168.446 SH | 19 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 17.397 SH | 02 Ekim 2026 | Günlük |
| WSML · iShares Trust | 0,05% | 3.911 SH | 11 Eylül 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,04% | 896.639 SH | 19 Ağustos 2026 | Günlük |
| TILT · FlexShares Trust | 0,02% | 4.212 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.482.796 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6.117 SH | 19 Ağustos 2026 | Günlük |
| ITOT · iShares Trust | 0,01% | 103.097 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,01% | 20.075 SH | 11 Eylül 2026 | Günlük |
| PTH · Invesco Exchange-Traded Fund Trust | 0,00% | 91 SH | 02 Ekim 2026 | Günlük |
| ISCB · iShares Trust | · | 3.478 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 10.938 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 37.682 SH | 11 Eylül 2026 | Günlük |
| SMMV · iShares Trust | · | 1.644 SH | 01 Eylül 2026 | Günlük |
SYRE Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 23 analist
AL
Medyan hedef
$121.00
+29,8%
11 47,8%
Güçlü Al
10 43,5%
Al
2 8,7%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
13 analist · 2026-09-30Ortalama hedef $120.08 +28,9%
← Tüm hedeflerin altında
Mevcut fiyat $93.19
Düşük$97.00
Ortalama$120.08
Yüksek$130.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | · |
| IONS | $12.92B | -33.2 | · | · | -68.1% | · |
| IMVT | $5.07B | -9.0 | 229.2% | · | -73.7% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 4, 2026